Pascal Besman discusses lurbinectedin accelerated approval with FDA

PharmaMar to submit New Drug Application (NDA) for lurbinectedin under accelerated approval in SCLC in the USA. Pascal Besman, Pharmamar COO discusses advantages and potential limitations of the new d... Author: PharmaMar Added: 08/22/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts